Literature DB >> 17710479

Is the routine check nephrostogram following percutaneous antegrade ureteric stent placement necessary?

Keng Chuan Soh1, Kiang Hiong Tay, Bien Soo Tan, Austin Mm Htoo, Richard Hg Lo, Shueh En Lin.   

Abstract

Our aim was to review our experience with percutaneous antegrade ureteric stent (PAUS) placement and to determine if the routinely conducted check nephrostogram on the day following ureteric stent placement was necessary. Retrospective review of patients who had undergone PAUS placement between January 2004 and December 2005 was performed. There were 83 subjects (36 males, 47 females), with a mean age of 59.9 years (range, 22-94 years). Average follow-up duration was 7.1 months (range, 1-24 months). The most common indications for PAUS placement were ureteric obstruction due to metastatic disease (n = 56) and urinary calculi (n = 34). Technical success was 93.2% (96/103 attempts), with no major immediate procedure-related complications or mortalities. The Bard 7Fr Urosoft DJ Stent was used in more than 95% of the cases. Eighty-one of 89 (91.0%) check nephrostograms demonstrated a patent ureteric stent with resultant safety catheter removal. Three check nephrostograms revealed distal stent migration requiring repositioning by a goose-snare, while five others showed stent occlusion necessitating permanent external drainage by nephrostomy drainage catheter reinsertion. Following PAUS placement, the serum creatinine level improved or stabilized in 82% of patients. The serum creatinine outcome difference between the groups with benign and malignant indications for PAUS placement was not statistically significant (p = 0.145) but resolution of hydronephrosis was significantly better (p = 0.008) in patients with benign indications. Percutaneous antegrade ureteric stent placement is a safe and effective means of relief for ureteric obstruction. The check nephrostogram following ureteric stent placement was unnecessary in the majority of patients.

Entities:  

Mesh:

Year:  2007        PMID: 17710479     DOI: 10.1007/s00270-007-9128-0

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  1 in total

1.  Methylene Blue Injection as an Alternative to Antegrade Nephrostography to Assess Urinary Obstruction After Percutaneous Nephrolithotomy.

Authors:  Matthew D Truesdale; Molly Elmer-Dewitt; Marco Sandri; Bogdana Schmidt; Ian Metzler; Adam Gadzinski; Marshall L Stoller; Thomas Chi
Journal:  J Endourol       Date:  2016-04       Impact factor: 2.942

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.